title: Cumulative cisplatin dose is not associated with event-free or overall survival in children with newly diagnosed average-risk medulloblastoma treated with cisplatin based adjuvant chemotherapy: report from the Children's Oncology Group.
abstract: BACKGROUND
  Survival rates for children with medulloblastoma have risen over the past decade, in part due to the addition of cisplatin-containing adjuvant chemotherapy. Total dose of cisplatin required for optimal treatment is unknown. The purpose of this study was to evaluate the survival outcomes based on cumulative cisplatin doses (CCD) in children with newly diagnosed average-risk medulloblastoma.
  
  
  METHODS
  CCD data were reviewed for 363 patients in a prospective study evaluating patients between 3 and 21 years with a newly diagnosed average-risk medulloblastoma and treated with craniospinal radiation and post-radiation cisplatin based adjuvant chemotherapy.
  
  
  RESULTS
  Eight-year event-free survival (EFS) and overall survival (OS) estimates were 78.2 ± 2.6% and 83.9 ± 2.4%, respectively. Only 73 patients received the protocol specified CCD of 600 mg/m(2), primarily due to mandated cisplatin toxicity-related dose reductions. The median CCD given to those without relapse or death on treatment was 487.5 mg/m(2). CCD, as a time-dependent covariate, was not associated with EFS (P = 0.54) or OS (P = 0.11). The 343 patients who completed chemotherapy failure-free were categorized into four groups according to CCD (n = 10; 75-150 mg/m(2)), (n = 26; 151-300 mg/m(2)), (n = 113; 301-450 mg/m(2)), and (n = 194; 451-600 mg/m(2)). There were no statistically significant differences in distributions of EFS (P = 0.53) or OS (P = 0.49) among these four groups.
  
  
  CONCLUSIONS
  CCD is not associated with EFS or OS suggesting that lower doses of cisplatin may be incorporated into future medulloblastoma trials, thereby limiting its toxicity profile without affecting survival. If ototoxicity is encountered, more stringent cisplatin dose modification/cessation rules seem warranted.
authors: Division of Pediatric Hematology/Oncology, Department of Pediatrics and Adolescent Medicine, Mayo Clinic, Rochester, Minnesota.
authors: Amulya A
authors: AA
authors: Nageswara Rao
authors: Dana J
authors: DJ
authors: Wallace
authors: Catherine
authors: C
authors: Billups
authors: James M
authors: JM
authors: Boyett
authors: Amar
authors: A
authors: Gajjar
authors: Roger J
authors: RJ
authors: Packer
mesh_terms: D000293:Adolescent; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D002528:Cerebellar Neoplasms / Q000188:drug therapy* / Q000401:mortality; D059248:Chemoradiotherapy; D017024:Chemotherapy, Adjuvant; D002648:Child; D002675:Child, Preschool; D002945:Cisplatin / Q000008:administration & dosage*; D018572:Disease-Free Survival; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D053208:Kaplan-Meier Estimate; D060046:Maintenance Chemotherapy; D008297:Male; D008527:Medulloblastoma / Q000188:drug therapy* / Q000401:mortality; D016016:Proportional Hazards Models; D012307:Risk Factors; D055815:Young Adult
chemical_list: D000970:Antineoplastic Agents; D002945:Cisplatin
keywords: average-risk medulloblastoma; cumulative cisplatin dose; survival outcomes
references: Neuro Oncol. 2014 Oct;16 Suppl 4:iv1-63
references: 25304271
references: Cancer. 2006 Jul 15;107(2):417-22
references: 16779793
references: Pediatr Neurosurg. 1990-1991;16(6):292-6
references: 2134738
references: Radiat Res. 2010 Dec;174(6):840-50
references: 21128808
references: Nat Genet. 2009 Dec;41(12):1345-9
references: 19898482
references: J Clin Oncol. 2007 Feb 20;25(6):708-14
references: 17228018
references: J Clin Oncol. 2008 Aug 1;26(22):3749-55
references: 18669462
references: Lancet Oncol. 2006 Oct;7(10):813-20
references: 17012043
references: J Clin Oncol. 2012 Jul 1;30(19):2408-17
references: 22547603
references: Lancet Neurol. 2007 Dec;6(12):1073-85
references: 18031705
references: J Clin Oncol. 2005 Dec 1;23(34):8588-96
references: 16314621
references: J Clin Oncol. 2006 Sep 1;24(25):4202-8
references: 16943538
references: Pediatrics. 2007 Nov;120(5):e1229-36
references: 17974716
references: Cancer. 1990 Feb 1;65(3):412-7
references: 2153428
references: J Otolaryngol. 1991 Jun;20(3):158-67
references: 1870163
references: Pharmacogenomics J. 2008 Feb;8(1):23-8
references: 17457342
references: J Child Neurol. 2009 Nov;24(11):1455-63
references: 19841433
references: Med Pediatr Oncol. 1991;19(4):295-300
references: 2056973
references: Med Pediatr Oncol. 1989;17(1):48-52
references: 2913475
references: Acta Neuropathol. 2012 Apr;123(4):465-72
references: 22134537
references: J Neurosurg. 1994 Nov;81(5):690-8
references: 7931615
references: Ear Hear. 1998 Oct;19(5):339-54
references: 9796643
references: Med Pediatr Oncol. 1988;16(5):368-9
references: 3185367
references: Arch Neurol. 2008 Nov;65(11):1419-24
references: 19001159
references: Semin Oncol. 2004 Oct;31(5):666-75
references: 15497120